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Background: The aim was to assess and compare reported sleep disturbances and objectively 
measured sleep in men and women with COPD compared with controls and also explore sex 
differences.
Methods: A total of 96 patients with COPD and 90 age- and sex-matched controls answered 
a sleep questionnaire, underwent ambulatory polysomnography, a post-bronchodilatory 
spirometry, and blood sampling.
Results: Of the patients with COPD, 51% reported sleep disturbances as compared with 31% 
in controls (P=0.008). Sleep disturbances were significantly more prevalent in males with 
COPD compared with controls, whereas there was no significant difference in females. The 
use of hypnotics was more common among patients with COPD compared with controls, both 
in men (15% vs 0%, P=0.009) and women (36% vs 16%, P=0.03). The men with COPD had 
significantly longer recorded sleep latency than the male control group (23 vs 9.3 minutes, 
P,0.001), while no corresponding difference was found in women. In men with COPD, those 
with reported sleep disturbances had lower forced vital capacity, higher C-reactive protein, 
myeloperoxidase, and higher prevalence of chronic bronchitis.
Conclusion: The COPD was associated with impaired sleep in men while the association was 
less clear in women. This was also confirmed by recorded longer sleep latency in male subjects 
with COPD compared with controls.
Keywords: chronic obstructive pulmonary disease, sleep, polysomnography, quality of sleep, sex
Background
The COPD is characterized by a poorly reversible airflow limitation resulting from 
chronic inflammation, primarily due to smoking exposure, and resulting in multiple 
extra pulmonary comorbidities. The patients with COPD often report sleep disturbances 
and studies have indicated patients with COPD as having more difficulty falling, main-
taining, and staying asleep, and also having more daytime sleepiness.1,2 In two large 
studies, approximately 40% of the patients with COPD reported sleep disturbances,3,4 
and there are also studies reporting a higher prevalence of insomnia, nightmares, and 
daytime sleepiness in this group.5 In addition, they also have a higher regular use of 
hypnotics.2,6 Restless legs syndrome which is frequently associated with insomnia is 
also more frequent among patients with COPD.7
Furthermore, nighttime dyspnea is prevalent in patients with COPD, and can 
impair and disrupt sleep and result in tiredness.8 Hypoventilation during sleep is 
more pronounced in patients with COPD due to factors such as air flow obstruction, 
hyperinflation, respiratory muscle dysfunction, decreased ventilatory response to 
hypercapnia, and/or hypoxia but also due to medications.9 Sleep-related disturbances 
in gas exchange are considered a consequence of the disease itself and being separate 
and distinct from that of sleep-disordered breathing10 and there is also no indication 
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that obstructive sleep apnea is more common among patients 
with COPD than in the general population.4
Most studies on COPD and sleep, using objective mea-
sures have aimed to study the effects on nighttime saturation 
and not sleep architecture,11 although some small studies 
investigating sleep in COPD with objective measures indicate 
higher prevalence of light non-rapid eye movement (REM) 
sleep stages and more fragmented sleep.12 In 16 patients with 
COPD investigated by Cormick et al, the patients displayed 
more sleep fragmentation, diminished slow wave, and REM 
sleep,2 and Fleetham et al showed shorter sleep duration and 
more sleep fragmentation in COPD than healthy controls.13 
Earlier studies indicate that there are sex differences both for 
subjective and objective sleep showing that women have more 
subjective sleep complaints although objectively measured 
sleep does not reflect this. Studies have also shown that women 
have increased slow-wave sleep (SWS) as compared with men 
at any given age.14 However, to our knowledge, there are no 
earlier studies investigating sex differences in COPD.
Therefore, the aim of this study was to assess and compare 
reported sleep disturbances and objectively measure sleep 
using polysomnography in a large group of subjects (men and 
women) with and without COPD. In addition, the aim was 
to explore factors (including inflammatory markers) related 
to reported sleep disturbances and objectively measure 
sleep and also to explore sex differences. We hypothesized 
that both subjective and objective sleep would be worse in 
patients with COPD. In addition, we hypothesized that poor 
sleep would be associated with increased inflammation and 
that there would be sex differences.
Patients and methods
In this case-control study, 100 patients with COPD (men 
and women) and 100 sex- and age-matched control subjects 
were recruited. The male and female patients with COPD 
came from respiratory outpatient clinics at the Uppsala Uni-
versity Hospital, Uppsala; or General Practitioner clinics in 
Uppsala, Sweden. Female controls were recruited from an 
ongoing population-based study of women,15 whereas healthy 
males were recruited from another population-based study.16 
Inclusion criteria for the patients were: 1) doctors diagnosed 
COPD (International Classification of Diseases 10: J44); 
2) forced expiratory volume in 1 second/forced vital capacity 
(FEV
1
/FVC) ratio ,70% after bronchodilation (with 400 µg 
salbutamol); 3) stable disease with no exacerbations in the 
last 4 weeks; and 4) a wish to participate in the study. The 
patients not able to undergo whole-night polysomnography 
in their own home, receiving supplemental oxygen, or on 
oral steroid treatment were excluded. Inclusion criteria for 
the controls were: 1) no reported diagnosed COPD; 2) FEV
1
/
FVC ratio $70%; and 3) a wish to participate in the study.
The data were gathered over 2 consecutive days. On the 
first day, subjects performed a spirometry both before and 
after bronchodilation, for securing or excluding the diagno-
sis and COPD. Spirometry confirmed the COPD diagnosis 
in 96 patients with COPD and excluded COPD in 90 of 
the controls. Following the spirometry subjects underwent 
anthropometric measurements, structured interviews, and 
answered questionnaires, they also received instructions 
regarding the ambulatory polysomnography and were fitted 
with polysomnography equipment. On the second day, the 
subjects returned with polysomnographic equipment, venous 
blood was sampled, and subjects answered a questionnaire 
on sleep and bronchodilatory use during the preceding night. 
Figure 1 shows a flow chart of the study.
Prior to the polysomnography, the participants filled in 
questionnaires, including questions on sleep-related issues 
and symptoms, somatic disease, medication and also ques-
tions on snoring, daytime sleepiness, physical activity, and 
tobacco use.
Subjective sleep disturbances were assessed using the 
question: “Do you have problems with your sleep?” with a 
“yes” or “no” answer, where answering “Yes” was considered 
indicating sleep disturbances. The sleep questionnaire also 
included questions on snoring, nocturnal reflux, nocturnal 
body movements, and nocturia. The questionnaire also 
evaluated subjective daytime symptoms such as not feel-
ing rested in the morning, daytime sleepiness, and daytime 
fatigue. All answers were indicated on a five-point scale: 
1 (never); 2 (seldom); 3 (sometimes); 4 (often); and 5 (very 
often).17,18 The participants scoring 3 to 5 on these questions 
were defined as an indication to the symptom. Furthermore, 
symptoms of restless leg syndrome were assessed by four 
questions on 1) desire to move the extremities; 2) motor 
restlessness; 3) worsening of symptoms at rest with at least 
temporary relief by activity; and 4) worsening of symptoms 
in the evening or night. Answering “yes” to two or more 
of the questions indicated symptoms of restless legs.19 The 
participants were also asked to state the use of hypnotics.
Symptoms of insomnia were assessed by three questions, 
one on difficulties initiating sleep (DIS); one on difficulty 
maintaining sleep, and one on early morning awakening.18,20 As 
in the questions on daytime symptoms, the participants rated 
their difficulties on a five-point scale where 1 indicated “no 
problems” and 5 meant “very severe problems”. The partici-
pants were considered to have the symptom if scoring 3–5.
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Health-related quality of life was evaluated in the patients 
using the St George Respiratory Questionnaire (SGRQ).21 The 
SGRQ is a disease-specific instrument designed to measure 
impact on overall health, daily life, and perceived well-being 
in patients with obstructive airway disease. The instru-
ment includes three components; one symptom component 
(frequency and severity), one component on activities that 
cause or are limited by breathlessness, and one component 
on impact on social functioning, psychological disturbances 
resulting from airways disease. Scores range from 0 to 100, 
with higher scores indicating more limitations.
Anxiety and depressive status were assessed in the 
patients with COPD using the Hospital Anxiety and Depres-
sion scale.22 This is a self-administered rating scale that was 
originally designed for the patients with physical illness.22 It 
is well-validated and has often been used in studies to identify 
the levels of anxiety and depression.23–25 The questionnaire 
consists of 14 questions with seven concerning anxiety and 
seven concerning depression. All questions are scored from 
0 to 3, yielding a maximum of 21 points for the anxiety scale 
and 21 points for the depression scale.
The participants answered questionnaires regarding 
respiratory and bronchitis symptoms and medication intake, 
using the questionnaires used in the European Community 
Respiratory Health Survey.26 Dyspnea severities were graded 
according to the Medical Research Council scale.27 Chronic 
bronchitis was defined as reporting having chronic phlegm 
at least 3 months per year in 2 consecutive years. The 
questionnaires also included a question on somatic disease 
where the participants were asked if they had any somatic 
disease(s) that required regular medical attention.18
Six questions assessed smoking habits.28 Based on the par-
ticipants’ responses they were categorized as “current smokers” 
or “nonsmokers” (ie, never smoked or had quit smoking at 
least 6 months before answering the questionnaire).
spirometry
Pre-bronchodilator spirometry was performed according to 
American Thoracic Society Standards using a Welch Allyn 
spirometer (Welch Allyn Ltd, Skaneateles Falls, NY, USA) 
and repeated 15 minutes after inhalation of 400 µg salbutamol 
via large-volume spacer. The best of three readings for both 
FEV
1
 and FVC was recorded, and expressed in liters and 
percentage of predicted normal using the European Com-
munity Coal and Steel data set.29
Polysomnography
The participants received instructions and had electrodes for 
polysomnography attached to the research facility to perform 
a whole-night polysomnography in their own home. Poly-
somnography was performed by using the ambulatory system 
EMBLA (Flaga Inc., Reykjavík, Iceland). A total of 16 channels 
were recorded and included two electro-encephalography leads 
(C3-A2 and C4-A1), two electrooculography leads, and three 
electromyography leads (submental, and left and right ante-
rior tibialis muscles). In addition, two airflow leads (oronasal 
???????????????????????????????????????????
???????????????????????????????????????????
?????????????????????
???????????????????????????????????????????
??????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????
???????? ????????
??????????????????????????????? ???????????????????????????????
Figure 1 Flowchart of the study.
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thermistor and nasal flow pressure sensor), one pharyngeal 
sound lead (piezo vibration sensor), and two respiratory effort 
leads (thoracic and abdominal piezo crystal transducers) were 
included. Furthermore, one oximeter lead (to measure oxygen 
saturation level and pulse from a finger probe), two electrocar-
diography leads, and one body position lead were included. 
The data were downloaded to the Somnologica reviewing 
analysis software (Version 2.0; Flaga Inc., Reykjavík, Iceland) 
and sleep was scored manually in 30-second epochs according 
to standard criteria.30 The polysomnography was considered 
acceptable when $4 hours of sleep were recorded and no 
registration had been lost for $20 minutes of the night.
The sleep-associated variables included total sleep time 
(TST), SWS (Stage 3; in minutes and as % of total sleep 
duration), Stage 1 and 2 sleep (in minutes and as % of total 
sleep duration), REM sleep (in minutes and as % of total 
sleep duration), sleep latency (SL), number of awakenings, 
apnea-hypopnea index (AHI; the average number of apneas 
and hypopneas/hour of sleep; apnea: complete cessation of 
nasal and oral airflow lasting $10 seconds; hypopnea: $50% 
reduction in airflow amplitude compared to baseline, in 
combination with a reduction $3% in oxyhemoglobin 
saturation, or an arousal), oxygen desaturation index (ODI; 
total desaturations $4%/hour of sleep), and lowest oxygen 
saturation during the night.
Blood sampling and anthropometric 
variables
Blood sampling was used to measure: highly sensitive 
C-reactive protein (CRP), Interleukin-6 (IL-6), myeloper-
oxidase (MPO), and Type B natriuretic protein, all in serum. 
The anthropometric variables height and weight were mea-
sured by a research nurse and body mass index (BMI) was 
calculated as weight (kg)/height2 (m2). Blood pressure was 
measured in the right arm after 15-minute rest in a supine 
position.
statistical analyses
Statistical analyses were performed using Stata 10 and Stata 
13 (StataCorp., College Station, TX, USA). Univariate 
analyses were conducted using the unpaired Student’s t-test 
or the chi-squared test to compare baseline data between 
groups. Associations between COPD and sleep were further 
analyzed using multiple linear regression analysis. Interac-
tion analyses were conducted to detect significant differ-
ences in the associations between sex and sleep. From this 
analysis, significant difference in the association between 
sex and sleep was detected, and therefore, all analyses were 
stratified by sex. A P-value ,0.05 was considered indicating 
a significant difference.
The study was approved by the Ethics Committee of the 
Medical Faculty at Uppsala University, and all participants 
in the study gave their written informed consent.
Results
Of all the patients with COPD, 51% reported having sleep 
disturbances compared to 31% of the controls (P=0.008). 
Both in patients with COPD and in controls sleep distur-
bances were more common among females than males. 
However, when stratifying by sex a statistically significant 
difference between patients with COPD and controls was 
found in men but not in women (Figure 2).
Females with COPD had a lower BMI than control 
females, while there was no difference in BMI among male 
patients with COPD and controls. Both men and women with 
COPD were more often smokers or ex-smokers, and they 
also had lower FEV
1
, FVC, and daytime oxygen saturation 
(SaO
2awake
) compared with controls. In addition, both male 
and female patients with COPD had higher levels of IL-6, 
and in male patients with COPD, CRP was also significantly 
increased. Sleep disturbances were significantly more preva-
lent in men with COPD compared with controls whereas there 
was no significant difference in women (Table 1).
Men with COPD significantly more often reported prob-
lems with nocturnal body movement and DIS compared with 
controls; results not seen in women. In both men and women, 
the use of hypnotics was more frequent among the patients 
with COPD compared with controls (Table 2).
Among the controls, females more often reported not 
feeling rested in the morning, daytime sleepiness, and day-
time fatigue compared with males. However, when compar-
ing patients with COPD to controls, these symptoms were 
??
??
??
??
??
??
??
??
? ???? ?????
????
????
????
???
???
????
???????????
???????
??????
Figure 2 reported sleep disturbances in men and women, with and without COPD.
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more common among male patients with COPD compared 
with controls, whereas there were no differences in women 
(Figure 3).
Among controls, females had longer SL and a shorter 
TST when compared to males. When patients with COPD 
were compared to controls, men with COPD had significantly 
longer SL than the male control group whereas women 
with COPD had a longer TST, a larger proportion of the 
night spent in SWS and a lower AHI and ODI than women 
without COPD. Both men and women with COPD had 
significantly lower oxygen saturation (SaO
2sleep
) during the 
night compared with controls (Table 3). When adjusting for 
age, BMI, smoking history, and AHI, only the association 
between TST and COPD in women (P,0.0001) and the 
association between SL and COPD in men (P,0.0001) 
remained statically significant. The correlations between SL 
and also TST and anxiety/depression were assessed in the 
patient group with COPD, where information on HAD score 
had been obtained. There were no significant relationships 
either in men or women (data not shown). In addition, there 
were no significant relationship between either TST or SL 
and the SGRQ scores, either in men or women with COPD 
(data not shown).
In the male group of participants reporting sleep dis-
turbances, there were no differences between patients with 
COPD and controls in any of the objective sleep measures 
Table 1 Characteristics of the study population (mean ± sD) or %
Characteristics Men Women
No COPD
(n=44)
COPD
(n=49)
P-value No COPD
(n=46)
COPD
(n=47)
P-value
age (years) 65±5.7 66±6.0 0.62 63±6.8 64±6.0 0.58
BMI (kg/m2) 28±4.4 28±4.0 0.61 28±4.8 24±5.1 0.0007
smoking history ,0.0001 ,0.0001
never smokers 48 0 47 0
ex-smokers 45 68 40 79
Current smokers 7 33 13 21
FeV1 (% predicted) 100±16 55±18 ,0.0001 108±16 54±19 ,0.0001
FVC (% predicted) 97±17 81±16 ,0.0001 113±17 92±24 ,0.0001
saO2awake (%) 95±1.4 93±2.6 0.0004 95±1.3 93±2.0 ,0.0001
CrP* mg/l 1.7 (1.3–2.3) 4.1 (3.2–5.2) ,0.0001 1.9 (1.3–2.9) 2.3 (1.7–3.1) 0.52
Il-6* 1.0 (0.66–1.4) 1.7 (1.3–2.4) 0.02 0.64 (0.40–1.0) 1.5 (1.2–2.1) 0.0007
MPO units 324 (274–383) 264 (224–312) 0.08 218 (149–318) 319 (256–398) 0.06
BnP* 78 (58–106) 99 (73–133) 0.28 79 (63–100) 110 (84–144) 0.07
reported sleep disturbances 9 37 0.002 55 67 0.25
Obstructive sleep apnea** 49 51 0.75 59 41 0.047
hypertension*** 41 35 0.61 29 28 0.90
Ischemic heart disease*** 14 23 0.25 2.4 12.8 0.07
Diabetes*** 6.8 12 0.38 9.0 0 0.03
Notes: *geometric mean (95% CI); **ahI $10/h; ***reported in questionnaire by the participant. Data in bold indicates variables with P-value ,0.05 for between group 
comparison.
Abbreviations: AHI, apnea-hypopnea index; BMI, body mass index; BNP, B natriuretic protein; CI, confidence interval; CRP, C-reactive protein; FEV1, forced expiratory 
volume in 1 second; FVC, forced vital capacity; Il-6, Interleukin-6; MPO, myeloperoxidase; saO2awake, daytime oxygen saturation; sD, standard deviation.
Table 2 self-reported nighttime symptoms and use of hypnotics (%)
Variables Men Women
No COPD
(n=44)
COPD
(n=49)
P-value No COPD
(n=46)
COPD
(n=47)
P-value
snoring 59 65 0.59 76 65 0.24
Nocturnal reflux 9.1 16 0.30 18 15 0.71
nocturnal body movements 14 35 0.02 44 37 0.47
nocturia 28 35 0.44 51 47 0.68
Difficulties initiating sleep 11 33 0.01 56 41 0.17
Difficulties maintaining sleep 25 43 0.07 38 47 0.38
early morning awakenings 30 35 0.65 52 63 0.30
symptoms of restless legs 11 16 0.49 51 61 0.35
Use of hypnotics 0 15 0.009 16 36 0.03
Note: Data in bold indicates variables with P-value ,0.05 for between group comparison.
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whereas the women with concomitant COPD and sleep 
disturbances had longer TST than controls with sleep 
disturbances (P=0.005), and this association remained 
significant when also adjusting for age, BMI, smoking 
history, and AHI (P=0.004).
When further dividing the groups with COPD by reported 
sleep disturbances, male patients with COPD along with 
sleep disturbances had lower FVC, higher CRP, and MPO 
and a higher prevalence of chronic bronchitis and ischemic 
heart disease compared with controls. There were no sta-
tistically significant differences in clinical characteristics 
between patients with COPD along with and without reported 
sleep disturbances in women (Table 4). The differences for 
FVC (P=0.01), CRP (P=0.045), MPO (P=0.047), chronic 
bronchitis (P=0.003), and ischemic heart disease (P=0.039) 
in men all remained significant when adjusting for age, 
BMI, smoking history, and AHI. In addition, adjusting also 
for HAD status did not significantly change the results (data 
not shown).
The association between health-related quality of life and 
reported sleep disturbances is presented in Figure 4. In men, 
sleep disturbances were associated with lower quality of life 
while no such significant association was found in women 
(Figure 4).
Discussion
The main finding of the present study is that despite an 
overall higher prevalence of sleep disturbances in women, 
the association between COPD and impaired sleep was more 
obvious in men. The association was also strengthened by 
recorded longer SL in men with COPD compared to men 
without COPD.
Sleep disturbances and daytime symptoms were signifi-
cantly related to COPD in men, and both male and female 
patients with COPD more often used hypnotics, compared 
with controls, results seen also in earlier studies.2,9 It is known 
that women in general use more hypnotics than men and 
also in the present study the use of hypnotics among women 
was high; however there are, to our knowledge, no studies 
on sex differences in patients with COPD regarding the use 
of hypnotics. Male patients with COPD had more nighttime 
symptoms compared with controls, whereas there was no 
significant difference in women. Male patients with COPD 
along with sleep disturbances also had more impact on quality 
of life. Sleep disturbances in patients with COPD are common 
and has been reported in several earlier studies. Klink and 
Quan have reported that 39% of patients with COPD along 
with nocturnal cough or wheezing indicate having difficulty 
initiating or maintaining sleep and that 29% of the patients 
reported daytime sleepiness.5 In addition, Geiger-Brown et al 
have shown associations between sleep quality and quality 
??
??
?? ??????? ?????? ???????
????? ?????????????? ???????????????????????????????????
??????
??????
??????
??
??
??
??
?
???
????
???
????
???????????????????????????????????????????????
???????????????????????????????????????????
Figure 3 reported daytime symptoms in men and women, with and without COPD.
Table 3 results from the polysomnography recordings (mean ± sD) and %
Variables Men Women
No COPD
(n=44)
COPD
(n=49)
P-value No COPD
(n=46)
COPD
(n=47)
P-value
TsT (minutes) 408±62 395±82 0.40 361±89 431±87 0.0003
sl* (minutes) 9.3 (6.7–13) 23 (17–31) ,0.0001 20 (14–28) 15 (11–19) 0.21
awakenings (number) 11±4.6 12±6.4 0.21 10±4.3 12±6.1 0.07
stage 1–2 (%) 79±8.3 82±8.4 0.08 77±8.2 72±9.2 0.01
stage 3 (%) 10±7.0 7.7±6.0 0.07 10±6.4 14±8.0 0.007
reM (%) 11±5.4 10±5.5 0.60 13±5.9 13±5.9 0.76
ahI* 10 (7.4–15) 9.5 (7.1–13) 0.66 13 (9.6–18) 8.6 (6.6–11) 0.04
ODI* 8.9 (6.1–13) 7.4 (5.4–10) 0.74 11 (8.1–15) 5.5 (4.0–7.6) 0.02
saO2sleep 94±1.6 92±2.7 0.0001 95±1.5 92±2.0 ,0.0001
Notes: *geometric mean (95% CI). Data in bold indicates variables with P-value ,0.05 for between group comparison.
Abbreviations: AHI, apnea-hypopnea index; CI, confidence interval; ODI, oxygen desaturation index; REM, rapid eye movement; SaO2sleep, significantly lower oxygen 
saturation during the night; sD, standard deviation sl, sleep latency; TsT, total sleep time.
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of life, where the quality of life scores were worse in poor 
sleepers compared with good sleepers.31 However, to our 
knowledge, there are no earlier studies investigating sex 
differences as the present study does.
Sleep in patients with COPD has been shown as frag-
mented, with diminished amounts of SWS and REM sleep.12 
McSharry et al showed that in a patient with COPD, cohort 
sleep efficiency was 66%±17% and there was also an altered 
sleep architecture with diminished periods of REM sleep.12 
The same study also showed that the daytime PaO
2
 (partial 
pressure of oxygen in the blood) correlated independently with 
sleep efficiency, whereas FEV
1
 positively correlated with sleep 
fragmentation.12 In the present study, men with COPD had 
significantly longer SL, and there was a trend for an associa-
tion between diminished amounts of SWS and COPD in men. 
It was also primarily men who reported sleep disturbances 
whereas women with COPD had longer TST and also more 
SWS compared with controls. However, although having 
Table 4 Characteristics of patients with COPD without and with sleep disturbances (mean ± sD) or %
Characteristics Men Women
No sleep disturbance
(n=31)
Sleep disturbance
(n=18)
P-value No sleep disturbance
(n=15)
Sleep disturbance
(n=30)
P-value
age (years) 67±6.4 63±4.6 0.051 65±5.7 64±6.2 0.36
BMI (kg/m2) 27±4.4 29±3.3 0.26 24±4.2 25±5.7 0.87
FeV1 % predicted 58±17 51±19 0.21 51±20 55±20 0.54
FVC % predicted 85±16 73±15 0.01 86±27 94±23 0.29
saO2awake 93±2.8 93±2.5 0.71 93±1.7 93±2.1 0.75
CrP* 3.3 (2.5–4.3) 5.9 (3.6–9.7) 0.03 2.0 (1.1–3.6) 2.5 (1.7–3.7) 0.45
Il-6* 1.6 (1.1–2.4) 2.0 (1.1–3.8) 0.48 1.6 (0.92–2.9) 1.4 (1.0–2.0) 0.64
MPO 224 (182–277) 357 (283–450) 0.006 263 (166–416) 363 (277–474) 0.18
BnP* 101 (69–151) 93 (55–157) 0.71 103 (58–181) 116 (84–159) 0.67
Ischemic heart disease** 13 41 0.03 13 13 0.99
Chronic bronchitis 21 76 ,0.0001 40 47 0.67
Notes: *geometric mean (95% CI); **reported in questionnaire by the participant. Data in bold indicates variables with P-value ,0.05 for between group comparison.
Abbreviations: BMI, body mass index; BNP, B natriuretic protein; CI, confidence interval; CRP, C-reactive protein; FEV1, forced expiratory volume in 1 second; FVC, forced 
vital capacity; Il-6, interleukin-6; MPO, myeloperoxidase; saO2awake, daytime oxygen saturation; sD, standard deviation.
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Figure 4 health-related quality of life, measured with st george respiratory Questionnaire, in men and women with COPD who do not report or do report having sleep 
disturbances.
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longer TST and more SWS, both patients with COPD and 
controls in the female group had normal to low values com-
pared with reported numbers in a general population.32,33
In this study, men with COPD reported more nighttime 
symptoms, such as nocturnal body movements, DIS, DMS, 
and also more problems with sleep disturbances compared 
with controls. The COPD has previously been associated 
with daytime sleepiness and poor quality of sleep34 and a large 
twin study in men showed that pulmonary disease was cor-
related with sleeping problems such as trouble falling asleep, 
staying asleep, waking often, and being tired when awake.35 
A case-control study in 52 patients with mild-to-moderate 
COPD and 52 controls showed patients with COPD to have 
less sleep efficiency, shorter TST, and lower mean nighttime 
oxygen saturation compared to controls. The patients with 
COPD were also significantly more likely to report symptoms 
such as difficulty in initiating and maintaining sleep compared 
with controls.36 However, there were no sex stratifications in 
that study.36
The present study show increased levels of IL-6 in 
patients with COPD of both sexes and increased CRP in 
men with COPD compared with controls. Male patients with 
COPD along with sleep disturbances also had higher levels 
of both CRP and MPO after controlling for confounders. The 
association between sleep disturbances, COPD, and systemic 
inflammation has been poorly investigated although there are 
studies showing increased systemic inflammation in COPD37 
and also studies showing increased systemic inflammation 
in subjects with sleep disturbances and sleep restriction.38 
In addition, results from population studies have indicated 
stronger associations between systemic inflammation and 
sleep in men than in women.39,40 Furthermore, in a study of 
53 patients with COPD, men with higher CRP values were 
associated with larger decline in FEV
1
 compared to women.41 
This could imply that increased inflammatory burden in men 
might worsen their sleep pattern and subsequently increase 
their sleep-related symptoms and disturbances although more 
studies in this field are needed.
This study was conducted in a sex-mixed cohort of 
patients with COPD and controls with larger groups than 
compared with earlier studies on sleep in COPD and good 
generalizability. Nonetheless, there are considerations when 
interpreting the results. First, all case-control studies may be 
subjected to selection bias. Second, this was a cross-sectional 
study and therefore we cannot conclude causality. Third, 
information on anxiety and depression and also health-related 
quality of life was only collected in the patient group and 
not in the controls. Therefore, we could not fully assess 
the impact these may have on our results. However, there 
was no correlation between objectively measured sleep and 
anxiety or depression in the COPD group where HAD score 
was measured. In addition, adjusting the analysis for subjec-
tive sleep disturbances for HAD score in the COPD group 
did not significantly change the results. Furthermore, there 
was no correlation between objectively measured sleep and 
health-related quality of life (SGRQ score) in the COPD 
group. Fourth, there was no question on napping during the 
day, a variable which may have an impact on both nighttime 
sleep and daytime function. Finally, the use of a cutoff of 
4 hours for adequate polysomnography could be argued to be 
too short and that it is possible that those with subjectively 
worse sleep tolerate recording equipment less well, and 
therefore, have shorter total recording time. We tested the 
hypothesis that those with subjectively worse sleep (“having 
sleep disturbances”) would have shorter total recording time 
compared with those without sleep disturbances. However, 
this relationship was not significant either in the whole group, 
in men or in women. In addition, the relationship was not 
significant either in the patients with COPD or in controls.
Conclusion
In this study, women had a higher overall prevalence of sleep 
disturbances and in controls longer SL and shorter TST. 
However, men with COPD reported more sleep disturbances 
compared with controls, and it was also more common in 
this group to report both daytime and nighttime symptoms. 
Both male and especially female patients with COPD 
indicated a high use of hypnotics whereas females both as 
a whole and in the COPD group showed better polysom-
nography data with longer TST than controls. In the group 
of male patients with COPD along with sleep disturbances 
higher CRP and MPO was seen and men with COPD also 
indicated lower quality of life. Therefore, we conclude that 
the associations between COPD and impaired sleep were 
clearer in men than in women and the association between 
reported impaired quality of sleep was also confirmed by 
recorded longer SL in men with COPD compared to men 
without COPD.
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